文献速递头颈部肿瘤放疗姑息放疗与转移瘤

根治性放疗提前中止:头颈部照射的启示

Premature discontinuation of curative radiation therapy: Insights from head and neck irradiation.
PubMed 文献 · Adv Radiat Oncol · 2017-10-23

本研究回顾性分析2010至2017年间某机构161例根治性放疗提前中止(PDCRT)患者,其中58例(36%)为头颈部照射。头颈部PDCRT最常见原因为违背医嘱中止(33%)、内科合并症(24%)和放疗毒性(17%);

要点

  • 头颈部PDCRT最常见原因为违背医嘱中止(33%),其次为内科合并症(24%)和放疗毒性(17%)。
  • 头颈部PDCRT后2年总生存率为61%,疾病特异生存率为78%。

核心结论

  • 头颈部根治性放疗提前中止最常见原因为违背医嘱中止,强调患者教育、症状优化、社会工作参与及早期整合支持服务的重要性。
  • 头颈部PDCRT后生存仍不理想,2年总生存率为61%。
  • 完成总剂量≥50 Gy似乎带来相对治疗获益。

研究设计与样本

  • 回顾性分析2010至2017年间某机构161例根治性放疗提前中止患者,其中36%为头颈部照射,共58例纳入分析。
  • 收集人口学、临床及治疗相关数据,采用寿命表法和log-rank检验分析生存。

主要发现

  • 大多数患者为男性(81%)、白人(67%)、≥60岁(59%)、居住地距医院≥10英里(60%)、单身(57%)、ECOG评分≥1(86%)、存在显著疼痛问题(67%),且放疗中断(66%)。
  • PDCRT最常见原因为违背医嘱中止(33%)、内科合并症(24%)和放疗毒性(17%)。
  • 导致PDCRT的合并症中,50%为急性心肺问题,43%为感染。
  • 中位随访时间15.9个月,2年总生存率和疾病特异生存率分别为61%和78%。
  • 非法物质滥用、心血管疾病和ECOG评分≥2的患者生存更差。

临床怎么用

  • 针对头颈部根治性放疗患者,应加强患者教育、优化放疗症状管理、早期引入社会工作及其他支持服务,以减少违背医嘱中止。
  • 对ECOG评分≥2、合并非法物质滥用或心血管疾病的患者,需关注其更差的生存预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Factors related to premature discontinuation of curative radiation therapy (PDCRT) are understudied. This study aimed to examine causes and clinical outcomes of PDCRT at our institution by investigating the most common anatomical site associated with PDCRT. METHODS AND MATERIALS: Among the 161 patients with PDCRT of various anatomic sites at our institution between 2010 and 2017, 36% received radiation to the head and neck region. Pertinent demographic, clinical, and treatment-related data on these 58 patients were collected. Survival was examined using the life-table method and log-rank test. RESULTS: The majority of patients were male (81%), white (67%), ≥60 years old (59%), living ≥10 miles away from the hospital (60%), single (57%), with Eastern Cooperative Oncology Group score ≥1 (86%), experiencing significant pain issues (67%), and had treatment interruptions in radiation therapy (RT; 66%). The most common reasons for PDCRT were discontinuation against medical advice (33%), medical comorbidity (24%), and RT toxicity (17%). Of the comorbidities leading to PDCRT, 50% was acute cardiopulmonary issues and 43% was infection. The mean follow-up time was 15.9 months, and the 2-year overall survival and disease-specific survival rates were 61% and 78%, respectively. Patients with illicit substance abuse, cardiovascular disease, and Eastern Cooperative Oncology Group score ≥2 had worse survival. A trend toward improved survival with total completed dose ≥50 Gy versus <50 Gy existed (74% versus 44%, respectively; P = .07). CONCLUSIONS: In this largest-to-date, modern analysis of PDCRT, the most common cause of discontinuation was discontinuation against medical advice, which underscores the importance of patient education, optimization of RT symptoms, involvement of social work, and integration of other supportive services early in treatment. Survival remains suboptimal after PDCRT for H&N tumors, with a 2-year overall survival rate of 61%. Completing >50 Gy appears to confer a relative therapeutic benefit.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lazarev S, Gupta V, Ghiassi-Nejad Z, et al. Premature discontinuation of curative radiation therapy: Insights from head and neck irradiation. Adv Radiat Oncol. 2017. PMID: 29556582. doi:10.1016/j.adro.2017.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。